Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10Stomach Neoplasms 5Colonic Neoplasms 5Carcinoma, Hepatocellular 4Rectal Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Biliary Tract Neoplasms 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neutropenia 1Neuroendocrine Tumors 1Malignant Tumor of Pancreas Metastatic to Liver 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Insulinoma 1Glucagonoma 1Gestational Trophoblastic Disease 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1

Interventions

irinotecan sucrosofate 1Leucovorin 1Gemcitabine 1Fluorouracil 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Malignant Tumor of Pancreas Metastatic to Liver × Leucovorin × Clear all
NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Sorrento Therapeutics, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Malignant Tumor of Pancreas Metastatic to Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡